Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 3 Hepatitis C, Chronic 2 Hepatitis C 2 Recurrence 1 Lymphoma, Non-Hodgkin 1 Liver Neoplasms 1 Liver Diseases 1 Hepatitis 1 Bronchiolitis Obliterans Syndrome 1

Interventions

Sorafenib 5 Blood Specimen Collection 4 lenvatinib 3 sintilimab 2 pembrolizumab 2 ledipasvir, sofosbuvir drug combination 2 halofantrine 2 camrelizumab 2 atezolizumab 2 Liver Transplantation 2 Immunotherapy 2 Control Groups 2 Bevacizumab 2 Antibodies 2 veliparib 1 trifluridine tipiracil drug combination 1 trametinib 1 toripalimab 1 titanium silicide 1 tislelizumab 1 rubitecan 1 repotrectinib 1 pevonedistat 1 ozanimod 1 linifanib 1 genexol-PM 1 gadolinium ethoxybenzyl DTPA 1 fluorocholine 1 fisogatinib 1 ficlatuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Liver Diseases × Sofosbuvir × Clear all

NCT02717949 2019-01-08

Optimal

University of Texas Southwestern Medical Center

Phase 4 Terminated

Hepatitis C, Liver Diseases, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡